Dutch experts on climate change adaptation join forces Fourteen Dutch knowledge institutes have joined forces to provide practical, demand-driven policy advice based on climate change adaptation.
Substances of very high concern hamper recycling Substances of very high concern (SVHC) can hamper the safe recycling of waste streams in the Netherlands. These substances occur in a wide range of waste streams.
Chemical legislation REACHes out to bio-based economy European REACH regulation on chemicals can provide benefits to companies that make or import bio-based substances.
Greenhouse Emission model suited for the authorisation of plant protection products Residues of plant protection products used in greenhouses may enter surface water upon discharge of nutrient solution and affect surface water organisms.
Building blocks for a definition of microplastics The Dutch National Institute for Public Health and the Environment, RIVM has described building blocks for a definition of microplastics.
Jacco Wallinga appointed extraordinary Professor at LUMC From 1 September, Jacco Wallinga will hold the chair in Mathematical Modelling of Infectious Diseases at the department of Medical Statistics and Bio-informatics of the Leiden University Medical Ce
Little incentive from pharmaceutical legislation to promote alternatives to animal testing Current pharmaceutical legislation does not impose any legal constraints on the use of alternatives to animal testing, but neither does it actively encourage the use of these alternatives.
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.